恩替卡韦治疗失代偿期乙肝肝硬化临床疗效分析

Clinical analysis of Entecavir on HBV-induced decompensated cirrhosis

目的探讨恩替卡韦(ETV)治疗失代偿期乙肝肝硬化的临床疗效。方法选择失代偿期乙肝肝硬化患者61例,随机分为2组。在综合性治疗治疗基础上,治疗组31例加用ETV,对照组30例加用阿德福韦酯(ADV)。观察症状减轻及复常情况,检测肝功能指标、血清透明质酸(HA)、乙肝五项标志物定量、乙肝病毒基因(HBV-DNA)以及肝脏磁共振扫描(MR)等。结果治疗组症状复常天数明显短于对照组,肝功能指标改善情况明显优于对照组。治疗组HBV-DNA阴转率、HBeAb阳转率、MR好转率明显高于对照组。结论 ETV治疗失代偿期乙肝肝硬化患者疗效确切,可不同程度逆转肝硬化,减少并发症,降低死亡率,且安全性好。

Objective To explore the clinical effect of Entecavir（ETV） on HBV-induced decompensated cirrhosis.Methods Sixty-one patients of HBV-induced decompensated cirrhosis were divided into treatment group（n=31,TG） and control group（n=30,CG）.After the basis treatment,TG received ETV,and CG received Adefovir Dipivoxil（ADV）.The improvement of symptoms,liver function,hyaluronic acid（HA）,five items of HBV,HBV-DNA,liver MR were detected before and after treatment.Results The recovery date of symptom in TG was shorter than that in CG.The liver function in TG was better than that in CG.The HBV-DNA negative rate,HBeAb positive rate and MR improving rate in TG were obviously higher than those in CG.Conclusion ETV has curative effect on HBV-induced decompensated cirrhosis,and it can not only change over the cirrhosis at different degrees,but also reduce complications.It has advantages of lower mortality and higher safety.